Lauren B. Gerson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lauren B. Gerson has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
George Triadafilopoulos
3 shared publicationsN. Ullah
Division of Gastroenterology, Stanford University School of Medicine, Stanford, CA, USA
3 shared publicationsG. Triadafilopoulos
Division of Gastroenterology and Hepatology, A 149, Stanford University School of Medicine, Stanford University, Stanford, CA 94305-5202, USA
2 shared publicationsAlvin Zfass
1 shared publicationAmine Hila
1 shared publicationAmit Agrawal
1 shared publication
Latest Publications
- 29 August 2013
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 45 (09) , 762-765
Capsule endoscopy and deep enteroscopy
Abbreviations: CO2, carbon dioxide; DBE, double-balloon enteroscopy; MGCE, magnetic-guided capsule endoscopy; PC, patency capsule; PEG, polyethylene glycol; SBE, single-balloon enteroscopy; VCE, video capsule endoscopy
- 29 August 2013
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 45 (09) , 762-765
Capsule endoscopy and deep enteroscopy
Abbreviations: CO2, carbon dioxide; DBE, double-balloon enteroscopy; MGCE, magnetic-guided capsule endoscopy; PC, patency capsule; PEG, polyethylene glycol; SBE, single-balloon enteroscopy; VCE, video capsule endoscopy
- Open Access
- 1 April 2013
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 5, 161-169
Comparison of health care resource utilization and costs among patients with GERD on once-daily or twice-daily proton pump inhibitor therapy
Background: The purpose of this study was to assess differences in health care resource utilization and costs associated with once-daily and twice-daily proton pump inhibitor (PPI) therapy. Most patients with gastroesophageal reflux disease (GERD) achieve symptom control on once-daily PPI therapy, but approximately 20%–30% require twice-daily dosing. Methods: Patients were ≥18 years of age with at least one medical claim for GERD and at least two PPI claims from HealthCore's Integrated Research Database (HIRDSM) during 2004–2009. Patients were continuously eligible for 12 months before and after the index date (date of first PPI claim). Based on PPI dosing throughout the post-index period (quantity of medication dispensed/number of days supply), patients were classified as once-daily (dose ≤ 1.5 pills per day) or twice-daily (≥1.5) PPI users. Results: The study cohort included 248,386 patients with GERD (mean age 52.8 ± 13.93 years, 56% females) of whom 90% were once-daily and 10% were twice-daily PPI users. The Deyo-Charlson Comorbidity Index for once-daily and twice-daily PPI users was 0.70 ± 1.37 and 0.89 ± 1.54, respectively (P < 0.05). More once-daily patients had claims for Barrett's esophagus (5% versus 2%, P < 0.0001) than twice-daily patients. Post-index, higher proportions of twice-daily patients had at least one GERD-related inpatient visit (7% versus 5%), outpatient visit (60% versus 49%), and office visit (48% versus 38%) versus once-daily patients (P < 0.0001). Mean total GERD-related health care costs were $2065 ± $6636 versus $3749 ± $11,081 for once-daily and twice-daily PPI users, respectively (P < 0.0001). Conclusion: Patients receiving twice-daily PPI therapy were likely to have more comorbid conditions and greater health care utilization and overall costs compared with patients using once-daily PPI therapy.
- 1 April 2013
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 5, 161-169
Open AccessComparison of health care resource utilization and costs among patients with GERD on once-daily or twice-daily proton pump inhibitor therapy
Background: The purpose of this study was to assess differences in health care resource utilization and costs associated with once-daily and twice-daily proton pump inhibitor (PPI) therapy. Most patients with gastroesophageal reflux disease (GERD) achieve symptom control on once-daily PPI therapy, but approximately 20%–30% require twice-daily dosing. Methods: Patients were ≥18 years of age with at least one medical claim for GERD and at least two PPI claims from HealthCore's Integrated Research Database (HIRDSM) during 2004–2009. Patients were continuously eligible for 12 months before and after the index date (date of first PPI claim). Based on PPI dosing throughout the post-index period (quantity of medication dispensed/number of days supply), patients were classified as once-daily (dose ≤ 1.5 pills per day) or twice-daily (≥1.5) PPI users. Results: The study cohort included 248,386 patients with GERD (mean age 52.8 ± 13.93 years, 56% females) of whom 90% were once-daily and 10% were twice-daily PPI users. The Deyo-Charlson Comorbidity Index for once-daily and twice-daily PPI users was 0.70 ± 1.37 and 0.89 ± 1.54, respectively (P < 0.05). More once-daily patients had claims for Barrett's esophagus (5% versus 2%, P < 0.0001) than twice-daily patients. Post-index, higher proportions of twice-daily patients had at least one GERD-related inpatient visit (7% versus 5%), outpatient visit (60% versus 49%), and office visit (48% versus 38%) versus once-daily patients (P < 0.0001). Mean total GERD-related health care costs were $2065 ± $6636 versus $3749 ± $11,081 for once-daily and twice-daily PPI users, respectively (P < 0.0001). Conclusion: Patients receiving twice-daily PPI therapy were likely to have more comorbid conditions and greater health care utilization and overall costs compared with patients using once-daily PPI therapy.
- 1 July 2011
- Published by Elsevier in Techniques in Gastrointestinal Endoscopy
- Vol. 13 (3) , 161-166
Realistic simulation of diagnostic endoscopy
- 1 July 2011
- Published by Elsevier in Techniques in Gastrointestinal Endoscopy
- Vol. 13 (3) , 161-166
Realistic simulation of diagnostic endoscopy
- 1 June 2010
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 105 (6) , 1266-1275
Arbaclofen Placarbil Decreases Postprandial Reflux in Patients With Gastroesophageal Reflux Disease
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)
- 1 June 2010
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 105 (6) , 1266-1275
Arbaclofen Placarbil Decreases Postprandial Reflux in Patients With Gastroesophageal Reflux Disease
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)
- 1 June 2010
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 71 (7) , 1211-1217.e2
Adverse events associated with anticoagulation therapy in the periendoscopic period
- 1 June 2010
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 71 (7) , 1211-1217.e2
Adverse events associated with anticoagulation therapy in the periendoscopic period
- 26 November 2009
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 55 (3) , 703-708
Long-Term Impact of Capsule Endoscopy in Patients Referred for Iron-Deficiency Anemia
- 26 November 2009
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 55 (3) , 703-708
Long-Term Impact of Capsule Endoscopy in Patients Referred for Iron-Deficiency Anemia
- 1 November 2009
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 7 (11) , 1177-1182.e3
Complications Associated With Double Balloon Enteroscopy at Nine US Centers
- 1 November 2009
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 7 (11) , 1177-1182.e3
Complications Associated With Double Balloon Enteroscopy at Nine US Centers
- 31 October 2009
- Published by Elsevier in Gastroenterology
- Vol. 137 (4) , 1197-1201
Capsule Endoscopy and Deep Enteroscopy: Indications for the Practicing Clinician
- 31 October 2009
- Published by Elsevier in Gastroenterology
- Vol. 137 (4) , 1197-1201
Capsule Endoscopy and Deep Enteroscopy: Indications for the Practicing Clinician
- 1 August 2009
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 7 (8) , 828-833
Recurrent Gastrointestinal Bleeding After Negative Upper Endoscopy and Colonoscopy
- 1 August 2009
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 7 (8) , 828-833
Recurrent Gastrointestinal Bleeding After Negative Upper Endoscopy and Colonoscopy
- 1 June 2009
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 7 (6) , 664-669
Long-Term Outcomes After Double-Balloon Enteroscopy for Obscure Gastrointestinal Bleeding
- 1 June 2009
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 7 (6) , 664-669
Long-Term Outcomes After Double-Balloon Enteroscopy for Obscure Gastrointestinal Bleeding